Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

Newsom announces $50 million contract to make California’s own brand of insulin

LOS ANGELES — California Gov. Gavin Newsom announced a new $50-million contract with the nonprofit generic drugmaker Civica to produce insulin under the state’s own label during a news conference Saturday in Downey.

Los Angeles Times

Michael Hiltzik: Eli Lilly is slashing insulin prices, but hold your applause

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

Los Angeles Times

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Why does insulin cost so much? Big Pharma isn’t the only player driving prices

Eli Lilly & Co.’s announcement that it is slashing prices for its major insulin products could make life easier for some diabetes patients while easing pressure on Big Pharma.

Tribune News Service

Seagen Nabs $43 Billion Pfizer Deal; Sanofi Scoops Up Provention Bio

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.

Investors Business Daily

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

Investors Business Daily

What is the UK’s Covid-19 spring booster programme and who is eligible for a vaccine?

London is still lagging behind parts of the country in terms of the vaccine uptake

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Woman, 42, told she would not live past childhood surpassed prognosis by decades

Katie Eliot said she has experienced ‘amazing things’ in her life, despite bleak medical predictions in her youth

Wales Online

Four keys to building your company's synthetic biology strategy

Big incumbent companies can't afford to fall behind in a new tech-and-science arms race.

Fortune

Woman’s rare condition left her with tumours all over her body

Katie Eliot, 42, was diagnosed with tuberous sclerosis at 18 years old

The Independent UK

Pfizer’s RSV vaccine just won an FDA panel’s backing for safety in older people. It's a market that will be worth up to $10 billion in a decade

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

Fortune

'I've had purple urine since I was in nappies, but only found out why aged 53'

Tony has Alkaptonuria (AKU), also known as black bone or black urine disease

Wales Online

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees

Moderna stock toppled Friday on mixed results for its flu shot — a rival to experimental vaccines from BioNTech, CureVac and Sanofi.

Investors Business Daily

A technicality could withhold RSV shots

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Yes, masks reduce the risk of spreading COVID, despite a review saying they don't

The question of whether and to what extent face masks work to prevent respiratory infections such as COVID and influenza has split the scientific community for decades.

Daily Mirror

Chloe Madeley went back to work just 8 weeks after giving birth as she 'needs the money'

Chloe Madeley - the daughter of TV stars Richard Madeley and Judy Finnigan - cut her maternity leave short because she didn't want to take her husband James Haskell's money

Investors Business Daily

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Fortune

People are much less likely to trust the medical system if they are from an ethnic minority, have disabilities, or identify as LGBTQ+, according to a first-of-its-kind study by Sanofi

In the U.S., 77% of people with disabilities, 69% of people from ethnic minorities, and 70% of LGBTQ+ people are less likely to trust the medical system.

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Drugmakers sued over insulin prices

California's Attorney General Rob Bonta sued the six major companies that dominate the U.S. insulin market

Tribune News Service

More states are doing what they can to cap insulin costs

In her early 20s, Karisa Hunt learned the hard lesson of what happens when someone rations life-preserving medication.

Tribune News Service

Eli Lilly, insulin makers sued by California over prices

Eli Lilly & Co., Novo Nordisk AS and Sanofi were sued by California over insulin prices, which the state claims are inflated through unfair and deceptive practices and disproportionately affect low-income households and people of color.

The Independent UK

California latest to sue drug companies over insulin prices

California says it will sue the companies that make and promote much of the nation's insulin

Radio France Internationale

Pharma giant Sanofi rolls out made-in-France Covid booster jab

French pharmaceutical giant Sanofi on Thursday launched its much-awaited Covid vaccine. The VidPrevtyn Beta booster jab was developed in France and will be available to anyone over 18 in chemists throughout the country.

Radio France Internationale

Medicine shortage hits as France grapples with health 'tripledemic'

France is one of several countries facing shortages of the widely used antibiotic amoxicillin and other medications, with surging illnesses among children increasing demand for the drugs.

Investors Business Daily

Small Biotech Kymera Just Snagged Sanofi's Interest — Here's Why

Kymera unveiled promising results for its skin-disease treatment on Wednesday, snagging interest from Sanofi and sending KYMR stock flying.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.